T1	p 43 66	myocardial infarction ]
T2	p 111 138	acute myocardial infarction
T3	p 227 235	patients
T4	p 239 251	thrombolytic
T5	p 291 328	106 males with Q-MI entered the study
T6	p 378 402	30 patients received TLT
T7	p 437 448	29 patients
T8	p 1038 1056	patients receiving
T9	p 1090 1126	ventricular systolic dysfunction and
T10	i 6 39	[ Neoton and thrombolytic therapy
T11	i 85 91	neoton
T12	i 141 145	MI )
T13	i 239 267	thrombolytic therapy ( TLT )
T14	i 343 375	treatment without TLT and neoton
T15	i 399 434	TLT with streptokinase preparations
T16	i 460 499	streptokinase preparations and neoton .
T17	i 551 567	echocardiography
T18	i 631 648	Holter monitoring
T19	i 670 671	.
T20	i 791 797	neoton
T21	i 976 982	neoton
T22	i 1019 1031	Neoton given
T23	i 1057 1060	TLT
T24	o 128 138	infarction
T25	o 144 169	) on systolic function of
T26	o 179 223	ventricle , arrhythmia and clinical symptoms
T27	o 498 534	. Left ventricular systolic function
T28	o 604 614	arrhythmia
T29	o 701 732	progression of left ventricular
T30	o 760 773	hospital stay
T31	o 843 884	end systolic and diastolic volumes of the
T32	o 949 972	. Antiarrhythmic action
T33	o 1070 1081	progression
T34	o 1085 1122	left ventricular systolic dysfunction